NASDAQ:TSRO - Tesaro Stock Price, Price Target & More

$53.02 +1.04 (+2.00 %)
(As of 04/25/2018 01:12 AM ET)
Previous Close$53.02
Today's Range$52.08 - $53.82
52-Week Range$50.67 - $168.92
Volume901,103 shs
Average Volume1.14 million shs
Market Capitalization$2.83 billion
P/E Ratio-5.78
Dividend YieldN/A
Beta1.34

About Tesaro (NASDAQ:TSRO)

Tesaro logoTesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900

Debt

Debt-to-Equity Ratio1.75%
Current Ratio4.74%
Quick Ratio4.39%

Price-To-Earnings

Trailing P/E Ratio-5.78
Forward P/E Ratio-5.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$223.33 million
Price / Sales13.01
Cash FlowN/A
Price / CashN/A
Book Value$4.58 per share
Price / Book11.58

Profitability

EPS (Most Recent Fiscal Year)($9.17)
Net Income$-496,120,000.00
Net Margins-222.15%
Return on Equity-126.44%
Return on Assets-67.17%

Miscellaneous

Employees715
Outstanding Shares54,800,000

How to Become a New Pot Stock Millionaire

Tesaro (NASDAQ:TSRO) Frequently Asked Questions

What is Tesaro's stock symbol?

Tesaro trades on the NASDAQ under the ticker symbol "TSRO."

How were Tesaro's earnings last quarter?

Tesaro (NASDAQ:TSRO) announced its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($3.35) EPS for the quarter, missing the Zacks' consensus estimate of ($2.39) by $0.96. The biopharmaceutical company earned $48.02 million during the quarter, compared to the consensus estimate of $51.78 million. Tesaro had a negative return on equity of 126.44% and a negative net margin of 222.15%. View Tesaro's Earnings History.

When is Tesaro's next earnings date?

Tesaro is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Tesaro.

What price target have analysts set for TSRO?

23 analysts have issued 12-month target prices for Tesaro's stock. Their predictions range from $48.00 to $199.00. On average, they anticipate Tesaro's share price to reach $128.2609 in the next twelve months. View Analyst Ratings for Tesaro.

What are Wall Street analysts saying about Tesaro stock?

Here are some recent quotes from research analysts about Tesaro stock:
  • 1. Cann analysts commented, "Tesaro released Q4 2017 results today with better than expected Zejula sales and higher than estimated R&D. Due to a certain amount of confusion and competition in the PARP market, we are adjusting our outlook to accommodate a slower adoption of Zejula, which is leading us to lower our target price from $199 to $122. We believe Zejula has the strongest data in the ovarian cancer maintenance setting and upside that could result from label expansion in other tumor types." (2/27/2018)
  • 2. HC Wainwright analysts commented, "Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration." (1/12/2018)
  • 3. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (1/11/2018)
  • 4. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
  • 5. Cowen Inc analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)

Who are some of Tesaro's key competitors?

Who are Tesaro's key executives?

Tesaro's management team includes the folowing people:
  • Mr. Leon O. Moulder Jr., Co-Founder, Chief Exec. Officer and Director (Age 61)
  • Dr. Mary Lynne Hedley, Co-Founder, Pres, Chief Operating Officer and Director (Age 55)
  • Mr. Timothy R. Pearson, Chief Financial Officer and Exec. VP (Age 50)
  • Dr. Jeffrey H. Hanke Ph.D., Chief Scientific Officer and Exec. VP of R&D (Age 61)
  • Dr. Martin H. Huber Jr., M.D., Chief Medical Officer and Sr. VP (Age 58)

Has Tesaro been receiving favorable news coverage?

Media coverage about TSRO stock has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tesaro earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Tesaro?

Shares of TSRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tesaro's stock price today?

One share of TSRO stock can currently be purchased for approximately $53.02.

How big of a company is Tesaro?

Tesaro has a market capitalization of $2.83 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. Tesaro employs 715 workers across the globe.

How can I contact Tesaro?

Tesaro's mailing address is 1000 WINTER STREET SUITE 3300, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


MarketBeat Community Rating for Tesaro (TSRO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  479 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  790
MarketBeat's community ratings are surveys of what our community members think about Tesaro and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tesaro (NASDAQ:TSRO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
23 Wall Street analysts have issued ratings and price targets for Tesaro in the last 12 months. Their average twelve-month price target is $128.2609, suggesting that the stock has a possible upside of 141.91%. The high price target for TSRO is $199.00 and the low price target for TSRO is $48.00. There are currently 9 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.612.582.582.52
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $128.2609$131.4348$148.7391$165.5652
Price Target Upside: 141.91% upside137.98% upside134.23% upside46.40% upside

Tesaro (NASDAQ:TSRO) Consensus Price Target History

Price Target History for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ:TSRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018Robert W. BairdReiterated RatingHoldLowView Rating Details
4/22/2018Lake Street CapitalSet Price TargetBuy$120.00LowView Rating Details
3/27/2018HC WainwrightReiterated RatingBuy$108.00HighView Rating Details
3/1/2018Morgan StanleyLower Price TargetOverweight -> Overweight$156.00 -> $146.00LowView Rating Details
2/28/2018Credit Suisse GroupReiterated RatingOutperform -> In-Line$150.00 -> $141.00HighView Rating Details
2/28/2018Wells FargoReiterated RatingOutperform$224.00 -> $122.00MediumView Rating Details
2/28/2018Leerink SwannReiterated RatingOutperform$123.00 -> $105.00HighView Rating Details
2/28/2018Royal Bank of CanadaLower Price TargetSector Perform$48.00HighView Rating Details
2/28/2018BarclaysLower Price TargetEqual Weight -> Equal Weight$135.00 -> $90.00HighView Rating Details
2/27/2018CannReiterated RatingBuy$199.00 -> $122.00MediumView Rating Details
2/22/2018Evercore ISIUpgradeIn-Line -> Outperform$88.00HighView Rating Details
1/18/2018Piper JaffrayReiterated RatingHold$65.00LowView Rating Details
1/2/2018CowenLower Price TargetMarket Perform$125.00 -> $80.00LowView Rating Details
12/20/2017CitigroupReiterated RatingBuy -> Buy$216.00 -> $135.00LowView Rating Details
11/28/2017ArgusSet Price TargetBuy$154.00LowView Rating Details
11/10/2017SunTrust BanksReiterated RatingBuy$160.00N/AView Rating Details
11/3/2017Jefferies GroupReiterated RatingHold$124.00N/AView Rating Details
9/11/2017WedbushReiterated RatingOutperform$160.00LowView Rating Details
9/10/2017OppenheimerReiterated RatingBuy$199.00LowView Rating Details
7/14/2017Janney Montgomery ScottReiterated RatingNeutralLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$175.00HighView Rating Details
6/20/2017Raymond JamesReiterated RatingMarket PerformMediumView Rating Details
6/20/2017Bank of AmericaReiterated RatingBuy$154.00HighView Rating Details
6/5/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$200.00 -> $195.00HighView Rating Details
11/4/2016UBSDowngradeOutperform -> Market PerformN/AView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Tesaro (NASDAQ:TSRO) Earnings History and Estimates Chart

Earnings by Quarter for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ:TSRO) Earnings Estimates

2018 EPS Consensus Estimate: ($9.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($3.15)($2.52)($2.85)
Q2 20185($2.63)($1.99)($2.38)
Q3 20185($2.74)($1.68)($2.26)
Q4 20185($2.58)($1.32)($2.04)

Tesaro (NASDAQ TSRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($2.56)N/AView Earnings Details
2/27/2018Q4 2017($2.39)($3.35)$51.78 million$48.02 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.16)($0.4660)$130.57 million$142.77 millionViewN/AView Earnings Details
8/8/2017Q2 2017($2.52)($2.82)$18.61 million$29.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.96)($2.60)$5.60 million$4.23 millionViewN/AView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
8/4/2016Q2 2016($1.69)($1.28)$10.49 million$36.56 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Tesaro (NASDAQ:TSRO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Tesaro (NASDAQ TSRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.70%
Insider Trading History for Tesaro (NASDAQ:TSRO)
Institutional Ownership by Quarter for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ TSRO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2018Orlando OliveiraSVPSell3,000$69.88$209,640.009,076View SEC Filing  
3/6/2018Peter J BarrisMajor ShareholderBuy145,532$57.40$8,353,536.80252View SEC Filing  
3/5/2018David M MottDirectorBuy61,437$58.83$3,614,338.7112,825View SEC Filing  
3/2/2018David M MottDirectorBuy68,302$55.56$3,794,859.1212,825View SEC Filing  
3/2/2018Enterprise Associates 13 L NewMajor ShareholderBuy54,642$55.56$3,035,909.52252View SEC Filing  
3/2/2018Leon O Moulder JrCEOBuy5,000$56.93$284,650.001,018,828View SEC Filing  
3/2/2018Martin H Jr. HuberSVPSell1,803$54.86$98,912.5811,647View SEC Filing  
3/2/2018Timothy R PearsonCFOSell2,575$54.86$141,264.507,303View SEC Filing  
3/1/2018Grant C. BogleVPSell1,809$54.85$99,223.65View SEC Filing  
3/1/2018Mary Lynne HedleyCOOSell3,855$54.86$211,485.3016,073View SEC Filing  
12/4/2017Martin H Jr. HuberSVPSell829$85.24$70,663.968,101View SEC Filing  
9/22/2017Martin H Jr. HuberSVPSell592$118.60$70,211.206,943View SEC Filing  
9/18/2017James O ArmitageDirectorSell10,000$117.13$1,171,300.0010,000View SEC Filing  
9/6/2017Edward C EnglishVPSell10,862$134.92$1,465,501.046,258View SEC Filing  
9/5/2017Orlando OliveiraSVPSell71$132.66$9,418.866,626View SEC Filing  
9/1/2017Grant C. BogleVPSell14,167$135.00$1,912,545.00View SEC Filing  
6/6/2017Edward C EnglishVPSell8,500$138.65$1,178,525.005,396View SEC Filing  
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.586,522View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.005,396View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69625View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.4710,000View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.831,842View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.961,250View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.003,500View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.6429,166View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.0012,500View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.003,500View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.152,479View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.003,500View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tesaro (NASDAQ TSRO) News Headlines

Source:
DateHeadline
Robert W. Baird Reaffirms Hold Rating for Tesaro (TSRO)Robert W. Baird Reaffirms Hold Rating for Tesaro (TSRO)
www.americanbankingnews.com - April 24 at 1:22 PM
BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of ZejulaBRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula
www.reuters.com - April 24 at 8:16 AM
TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®
finance.yahoo.com - April 24 at 8:16 AM
Lake Street Capital Analysts Give Tesaro (TSRO) a $120.00 Price TargetLake Street Capital Analysts Give Tesaro (TSRO) a $120.00 Price Target
www.americanbankingnews.com - April 23 at 9:18 AM
Tesaros (TSRO) "Outperform" Rating Reaffirmed at Wells FargoTesaro's (TSRO) "Outperform" Rating Reaffirmed at Wells Fargo
www.americanbankingnews.com - April 20 at 8:01 PM
Bank of America Reiterates "Buy" Rating for Tesaro (TSRO)Bank of America Reiterates "Buy" Rating for Tesaro (TSRO)
www.americanbankingnews.com - April 20 at 8:00 PM
Tesaro (TSRO) Downgraded by BidaskClub to Strong SellTesaro (TSRO) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - April 20 at 11:17 AM
TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 19 at 5:40 PM
Tesaro Sees Unusually Large Options Volume (TSRO)Tesaro Sees Unusually Large Options Volume (TSRO)
www.americanbankingnews.com - April 18 at 7:02 AM
Tesaro Sees Unusually High Options Volume (TSRO)Tesaro Sees Unusually High Options Volume (TSRO)
www.americanbankingnews.com - April 18 at 7:02 AM
ValuEngine Lowers Tesaro (TSRO) to SellValuEngine Lowers Tesaro (TSRO) to Sell
www.americanbankingnews.com - April 17 at 10:21 PM
Tesaro (TSRO) Rating Lowered to Strong Sell at BidaskClubTesaro (TSRO) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 17 at 12:21 PM
Today’s Research Reports on Trending Tickers: Bristol-Myers Squibb and TESAROToday’s Research Reports on Trending Tickers: Bristol-Myers Squibb and TESARO
finance.yahoo.com - April 17 at 8:26 AM
TESARO (TSRO) Reports Summarized Initial Data from Phase 1 GARNET trial of TSR-042 (anti-PD-1 antibody)TESARO (TSRO) Reports Summarized Initial Data from Phase 1 GARNET trial of TSR-042 (anti-PD-1 antibody)
www.streetinsider.com - April 16 at 5:28 PM
BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACRBRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR
www.reuters.com - April 16 at 9:15 AM
TESARO Summarizes TSR-042 Clinical Data Presented at AACRTESARO Summarizes TSR-042 Clinical Data Presented at AACR
globenewswire.com - April 16 at 9:15 AM
Tesaro Expected to Earn FY2020 Earnings of ($1.94) Per Share (TSRO)Tesaro Expected to Earn FY2020 Earnings of ($1.94) Per Share (TSRO)
www.americanbankingnews.com - April 16 at 3:03 AM
Tesaro (TSRO) Expected to Post Quarterly Sales of $56.68 MillionTesaro (TSRO) Expected to Post Quarterly Sales of $56.68 Million
www.americanbankingnews.com - April 15 at 3:45 AM
Tesaro: Time To BuyTesaro: Time To Buy
seekingalpha.com - April 13 at 5:25 PM
Tesaro (TSRO) Expected to Post Earnings of -$2.77 Per ShareTesaro (TSRO) Expected to Post Earnings of -$2.77 Per Share
www.americanbankingnews.com - April 13 at 3:24 PM
BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In IsraelBRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel
www.reuters.com - April 13 at 8:33 AM
Tesaro (TSRO) Receives Consensus Recommendation of "Buy" from AnalystsTesaro (TSRO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 7:43 PM
Tesaros (TSRO) "Overweight" Rating Reiterated at Morgan StanleyTesaro's (TSRO) "Overweight" Rating Reiterated at Morgan Stanley
www.americanbankingnews.com - April 11 at 5:35 PM
TESARO (TSRO) Announces Exclusive Distribution Agreement with Medison Pharma to Commercialize ZEJULA in IsraelTESARO (TSRO) Announces Exclusive Distribution Agreement with Medison Pharma to Commercialize ZEJULA in Israel
www.streetinsider.com - April 11 at 8:42 AM
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in IsraelTESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
finance.yahoo.com - April 11 at 8:42 AM
Tesaro (TSRO) Downgraded to "Sell" at ValuEngineTesaro (TSRO) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 7 at 8:19 PM
Tesaro (TSRO) Stock Rating Lowered by Zacks Investment ResearchTesaro (TSRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:50 PM
Tesaro (TSRO) Given Neutral Rating at Piper JaffrayTesaro (TSRO) Given Neutral Rating at Piper Jaffray
www.americanbankingnews.com - April 6 at 12:11 PM
Barclays Begins Coverage on Tesaro (TSRO)Barclays Begins Coverage on Tesaro (TSRO)
www.americanbankingnews.com - April 6 at 10:58 AM
Zacks Investment Research Upgrades TESARO (TSRO) to "Hold"Zacks Investment Research Upgrades TESARO (TSRO) to "Hold"
www.americanbankingnews.com - April 1 at 7:24 AM
TESARO (TSRO) Stock Rating Reaffirmed by Piper JaffrayTESARO (TSRO) Stock Rating Reaffirmed by Piper Jaffray
www.americanbankingnews.com - March 31 at 12:54 PM
TESARO (TSRO) Given New $80.00 Price Target at CowenTESARO (TSRO) Given New $80.00 Price Target at Cowen
www.americanbankingnews.com - March 31 at 11:47 AM
Zacks: Brokerages Anticipate TESARO Inc (TSRO) Will Announce Quarterly Sales of $57.59 MillionZacks: Brokerages Anticipate TESARO Inc (TSRO) Will Announce Quarterly Sales of $57.59 Million
www.americanbankingnews.com - March 29 at 4:55 AM
Morgan Stanley Remains Bullish on TESARO (TSRO)Morgan Stanley Remains Bullish on TESARO (TSRO)
www.streetinsider.com - March 28 at 5:19 PM
Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBios ANB020, Tesaro Reports Promising DataYour Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data
seekingalpha.com - March 28 at 8:03 AM
Tesaro Wants a Stronger Grip in Ovarian CancerTesaro Wants a Stronger Grip in Ovarian Cancer
finance.yahoo.com - March 28 at 8:02 AM
 Brokerages Expect TESARO Inc (TSRO) Will Announce Earnings of -$2.77 Per Share Brokerages Expect TESARO Inc (TSRO) Will Announce Earnings of -$2.77 Per Share
www.americanbankingnews.com - March 27 at 3:18 PM
TESARO (TSRO) Earns "Buy" Rating from HC WainwrightTESARO (TSRO) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 27 at 10:07 AM
Technical Perspectives on Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and VerastemTechnical Perspectives on Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem
www.prnewswire.com - March 27 at 8:14 AM
TESARO (TSRO): TOPACIO As Expected - Piper JaffrayTESARO (TSRO): TOPACIO As Expected - Piper Jaffray
www.streetinsider.com - March 27 at 8:14 AM
Analyzing TESARO (TSRO) and Cytori Therapeutics (CYTX)Analyzing TESARO (TSRO) and Cytori Therapeutics (CYTX)
www.americanbankingnews.com - March 27 at 8:09 AM
TESARO (TSRO) Raised to Sell at BidaskClubTESARO (TSRO) Raised to Sell at BidaskClub
www.americanbankingnews.com - March 26 at 10:58 PM
TESARO (TSRO) Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in ...TESARO (TSRO) Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in ...
www.streetinsider.com - March 26 at 5:29 PM
TESAROs Zejula + Mercks Keytruda shows positive effect in platinum-resistant ovarian cancer; shares up 2% after hoursTESARO's Zejula + Merck's Keytruda shows positive effect in platinum-resistant ovarian cancer; shares up 2% after hours
seekingalpha.com - March 26 at 5:29 PM
Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian CancerData From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
finance.yahoo.com - March 26 at 5:29 PM
Credit Suisse Reiterates Outperform on TESARO (TSRO) Ahead of SGO ConferenceCredit Suisse Reiterates Outperform on TESARO (TSRO) Ahead of SGO Conference
www.streetinsider.com - March 26 at 9:13 AM
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Tesaro, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2018 - TSRODEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Tesaro, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2018 - TSRO
finance.yahoo.com - March 19 at 5:28 PM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Tesaro, Inc. (TSRO) and Lead Plaintiff Deadline - March 19, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Tesaro, Inc. (TSRO) and Lead Plaintiff Deadline - March 19, 2018
finance.yahoo.com - March 19 at 5:28 PM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against TESARO, Inc. And Reminds Investors with Losses Exceeding $100,000 to Contact the FirmDEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against TESARO, Inc. And Reminds Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - March 19 at 5:28 PM
TESARO Inc (TSRO) Receives Consensus Recommendation of "Buy" from BrokeragesTESARO Inc (TSRO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 7:42 PM

SEC Filings

Tesaro (NASDAQ:TSRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tesaro (NASDAQ:TSRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tesaro (NASDAQ TSRO) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.